Inflammatory Bowel Disease (IBD)

  1. Home
  2. Health
  3. Inflammatory Bowel Disease (IBD)
IBS and IBD In The News

FDA Approves New Drug for Ulcerative Colitis

Salix Pharmaceuticals July 24, 2000
  Other News

A new drug, COLAZAL (balsalazide disodium) has been approved by the FDA for use in mild to moderate Ulcerative Colitis. The drug works by releasing the anti-inflammatory medication in the colon.

COLAZAL is a sulfa-free version of a 5-ASA. The active ingredient in sulfasalazine, a drug commonly used to treat ulcerative colitis, is sulfapyridine. The sulfapyridine is responsible for the side effects. COLAZAL uses a less toxic carrier molecule than sulfapyridine.

Currently COLAZAL is approved for up to 12 weeks of therapy. Side effects reported included abdominal pain and headaches. Salix expects to introduce COLAZAL into the United States in the first quarter of 2001. COLAZAL is currently available in Europe.

Full Story

Featured Links

Salix Pharmaceuticals
Salix Pharmaceuticals press release.

COLAZAL Home Page
Get notified when COLAZAL is available.

Subscribe to the Newsletter
Name
Email

Explore Inflammatory Bowel Disease (IBD)

About.com Special Features

Do I Have Allergies?

Are your symptoms merely irritating, or could they be a sign of allergies? More >

Preventing Headaches

The best way to treat a headache is to prevent it. Learn how. More >

We comply with the HONcode standard for trustworthy health information: verify here.

Inflammatory Bowel Disease (IBD)

  1. Home
  2. Health
  3. Inflammatory Bowel Disease (IBD)

©2009 About.com, a part of The New York Times Company.

All rights reserved.